Xella Health Integrated Its Diagnostics With Oura

The health platform now incorporates wearable data to improve personalized care plans for women.

Updated on Sept. 28, 2026 in Women’s Health

Xella Health Integrated Its Diagnostics With Oura

Live Poll

Do you trust that new health-tech platforms can improve the quality of diagnostic care for women?

Xella Health has integrated its precision health platform with Oura, allowing users to share heart rate, sleep, and menstrual cycle data. The platform currently screens for over 130 conditions to help address systemic delays in women's health diagnoses.

Why it matters

This partnership aims to provide clinicians with longitudinal health context to develop more effective, personalized care plans. By targeting specific symptoms like fatigue and pelvic pain, the tool seeks to reduce the diagnostic gap that leaves many women waiting years for answers.

The Xella platform screens for over 130 conditions with an annual membership cost of $499. The integration pulls data from Oura, a company valued at approximately $11 billion, which previously launched its own Menopause Impact Scale.

The players

Xella Health

This women's precision health platform screens for over 130 conditions using biomarker mapping.

Oura

This wearable device company is valued at approximately $11 billion and tracks biometric data like sleep and temperature.

The details

Xella maps relationships across more than 100 biomarkers simultaneously, tracking trajectories against individual baselines to identify health trends. The system is currently available in 48 U.S. states, though it remains inaccessible to residents of New York and New Jersey until 2027.

May 2026: Oura launched its Menopause Impact Scale.
September 23, 2026: Xella announced the integration with Oura.
End of 2026: Xella expects to launch a CLIA-route endometriosis risk tool.

Health Landscape

This integration follows a pattern set by the 1993 FDA reversal of rules excluding women from drug trials by addressing the historical exclusion of female patients in medical research. It signifies a transition toward using longitudinal, patient-generated data to overcome long-standing diagnostic inequities.

Users can now leverage their wearable data to gain more precise insights into their health trajectories and potential conditions. The service is currently available to residents in 48 states, though those in New York and New Jersey must wait until 2027 for access.

The takeaway

Integrating wearable biometric data with diagnostic platforms offers a promising path to bridging the gender gap in clinical diagnosis. Patients should consider how their own daily health tracking might contribute to more comprehensive discussions with their healthcare providers.

What happens next

Xella is preparing to close a seed funding round targeting between $8 million and $10 million and plans to launch a new endometriosis risk tool by the end of 2026.